報價延遲最少15分鐘:2025/08/23 15:14 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.04 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2,942.24/-93.53
|
|
企業價值
5.54M
|
| 資產負債 |
|
每股賬面淨值
2.61
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
133.99K
|
|
每股收益
0.19
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/23 15:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. |
